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The small glutamine-rich, tetratricopeptide repeat-containing protein alpha (SGTA) is an
emerging player in the quality control of secretory and membrane proteins mislocalized
to the cytosol, with established roles in tail-anchored (TA) membrane protein biogenesis.
SGTA consists of three structural domains with individual functions, an N-terminal
dimerization domain that assists protein sorting pathways, a central tetratricopeptide
repeat (TPR) domain that mediates interactions with heat-shock proteins, proteasomal,
and hormonal receptors, and viral proteins, and a C-terminal glutamine rich region that
binds hydrophobic substrates. SGTA has been linked to viral lifecycles and hormone
receptor signaling, with implications in the pathogenesis of various disease states.
Thus far, a range of biophysical techniques have been employed to characterize SGTA
structure in some detail, and to investigate its interactions with binding partners in
different biological contexts. A complete description of SGTA structure, together with
further investigation into its function as a co-chaperone involved quality control, could
provide us with useful insights into its role in maintaining cellular proteostasis, and
broaden our understanding of mechanisms underlying associated pathologies. This
review describes how some structural features of SGTA have been elucidated, and what
this has uncovered about its cellular functions. A brief background on the structure and
function of SGTA is given, highlighting its importance to biomedicine and related fields.
The current level of knowledge and what remains to be understood about the structure
and function of SGTA is summarized, discussing the potential direction of future research.
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INTRODUCTION
Protein quality control networks have evolved to deal with the burden of transiently unfolded and
terminally misfolded proteins a cell has to face, that result from inefficiencies in protein folding,
assembly and targeting (Wickner et al., 1999). The small glutamine-rich, tetratricopeptide repeat-
containing protein alpha (SGTA) is a co-chaperone involved in a specific branch of the global
cellular quality control network that determines the fate of secretory and membrane proteins that
mislocalize to the cytosol (Leznicki and High, 2012; Wunderley et al., 2014). SGTA recognizes
surface exposed regions of hydrophobicity on newly synthesized tail-anchored (TA) proteins
Roberts et al. SGTA Review
and mislocalized proteins (MLPs), and shields them from the
aqueous cytosol thus preventing them from misfolding, forming
undesirable protein-protein interactions, and from aggregation.
Upon stabilization of these exposed hydrophobic regions, the
subsequent fate of the proteins is determined, whichmay result in
refolding to their native conformation, targeting to their correct
destination or being marked for degradation (Leznicki and High,
2012; Leznicki et al., 2013, 2015; Wunderley et al., 2014). This
review collates and integrates the current literature surrounding
SGTA structure, function and interactions.
SGTA was first identified in complex with viral proteins
(Callahan et al., 1998; Cziepluch et al., 1998) and has emerged as
a key regulator in macromolecular quality control, in addition to
its established roles in the biogenesis of TA membrane proteins,
and proposed roles in hormone receptor signaling (Leznicki and
High, 2012; Leznicki et al., 2013; Philp et al., 2013; Wunderley
et al., 2014). SGTA has been found to localize predominantly to
the cytoplasm, however its presence in the nucleus has also been
detected (Philp et al., 2013). Due to its ubiquitous expression
in human tissues, and interactions with many different proteins
including HIV-1 encoded proteins Vpu and Gag, hormone
receptors andmyostatin, SGTA is associated with both health and
disease (Callahan et al., 1998; Kordes et al., 1998; Schantl et al.,
2003; Wang et al., 2003).
STRUCTURAL OVERVIEW OF SGTA
Human SGTA is a 34 kDa protein made up of 313 amino
acids that is ubiquitously expressed across all tissue types to
varying levels (Cziepluch et al., 1998; Kordes et al., 1998). It
assembles as a homodimer, with each chain comprising three
structural domains (Figure 1A): an N-terminal dimerization
domain (residues 1–69) followed by a flexible linker of around
14 residues, a central tetratricopeptide repeat (TPR) domain
(residues 86–208) and a C-terminal domain (residues 211–313)
which includes a 39 amino acid glutamine rich region (amino
acids 274–313). SGTA is highly conserved in different eukaryotes,
and in particular shows significant sequence homology amongst
metazoans (Figure 1B). The N-terminal and TPR domain
boundaries are clearly identifiable from sequence alignments,
with the central TPR repeats being the most conserved. The C-
terminal domain incorporates stretches of glutamine residues,
the positions of which are conserved in higher eukaryotes.
Additionally, the glutamine-rich region exhibits strong similarity
in metazoans, with the presence of C-terminal NNP repeats that
are conserved across all phyla.
SGTA is unique in being the only TPR-containing steroid
receptor co-chaperone known to form a homodimer (Buchanan
et al., 2007). This dimerization ability was initially attributed to
the TPR domain, which is capable of inter- and intra-molecular
interactions in other proteins (Hirano et al., 1990; Cziepluch
et al., 1998). However, it was observed in a brain-specific isoform
(β-SGT), and later in SGTA, that homo-dimerization is mediated
by the N-terminus (Tobaben et al., 2003; Liou and Wang, 2005).
In addition, the dimer is thought to be elongated, with the
three domains adjacent to each other (Liou and Wang, 2005;
Worrall et al., 2008; Darby et al., 2014). Evidence for this is
gleaned from the reported hydrodynamic radius of its C. elegans
equivalent (Sgt2) which has been observed to be larger than that
of a globular protein (Worrall et al., 2008). Small angle X-ray
scattering (SAXS) studies concur with an elongated arrangement
of the yeast Sgt2 dimer devoid of its C-terminal domain, with
full length Sgt2 showing characteristics of a partially folded
protein (Chartron et al., 2011). Apart from the above, there is
no structural information of domain organization in the context
of the full-length protein and the lack of conservation of the
linker between the N-terminal domain and the TPR, together
with its length (10–15 amino acids) suggests the presence of a
flexible connection between these two domains. Apart from the
N-terminal dimerization, no further evidence of intra- or inter-
domain contacts have been observed thus far in fully assembled
SGTA dimers.
Contrary to our understanding of the full-length dimer,
there have been several high-resolution structural studies on
excised SGTA domains. The structure of SGTA TPR domain
was determined by X-ray crystallography and was the first of
its three domains to be structurally elucidated (Dutta and Tan,
2008). In addition, the structure of its N-terminal domain has
been extensively characterized, which has provided insights into
its role in TA protein insertion pathways, together with details of
its association with other key effectors involved in MLP quality
control pathways, such as the BAG6 complex (Chartron et al.,
2011; Simon et al., 2013a,b; Darby et al., 2014). However, the C-
terminal region of SGTA is yet to be structurally characterized,
hence the nature and extent of its hydrophobic substrate-binding
site, along with mechanistic details pertaining to its interactions
with TA proteins and MLPs, remain poorly understood. A
summary of all currently solved SGTA and Sgt2 structures is
shown in Table 1.
N-TERMINAL DIMERIZATION DOMAIN
The N-terminal homodimerization domain of SGTA is formed
of four α-helices in each constituent protomer (α1 residues 3–
21, α2 residues 26–43, α3 residues 47–52, and α4 residues 58–67)
connected by short loops, which arrange into a unique helical
fold (Figure 2A). The dimer interface is made up of hydrophobic
residues that form a tight interaction, resembling the core of a
globular protein (Figure 2B; Simon et al., 2013b; Darby et al.,
2014). This characteristic fold is conserved in the N-terminal
domain of the yeast homolog Sgt2, presenting an RMSD of 2.41Å
between the two structures (Darby et al., 2014; Figure 2C).
The N-terminal domain of SGTA is responsible for its
interactions with the ubiquitin-like (UBL) domains present
in the BAG6 complex (Simon et al., 2013b; Darby et al.,
2014). The N-terminal domain dimer presents a negatively
charged surface, arising primarily from residues present in
the second alpha helix (Asp27, Glu30, Glu33, and Glu40),
that recognize a single UBL domain. The UBL exhibits a
positively charged region (up to 5 arginine or lysine residues)
at which binding is mediated through electrostatic interactions.
In addition, there are some apolar residues in both proteins
that are buried in the interface creating further stabilization of
the complex through hydrophobic interactions (Figure 2D; in
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FIGURE 1 | SGTA sequence alignment. (A) Full length SGTA is made up of 313 residues: an N-terminal homodimerization domain (residues 1–69) followed by a
14-residue linker, three TPR repeats with a distinct capping helix (residues 86–208) and a C-terminal domain (residues 211–313) including a Q-rich region (residues
274–313). (B) Sequences of SGTA and its homologs across the phyla have been aligned, and domains annotated with reference to the human SGTA sequence. C.
elegans, D. rerio, and A. fumigatus appear to have longer N-terminal extensions compared to both mammalian and yeast equivalents. The central TPR repeats are the
most conserved, however the TPR capping helix (helix 7) exhibits lower conservation in fungal species than in metazoans. The glutamine-rich region, present in the
C-terminal domain, also exhibits greater similarity in metazoans, with the presence of NNP repeats conserved across all phyla.
SGTA mainly Cys38 and Val34, and in UBLs two conserved
positions of leucine/isoleucine; Chartron et al., 2012). The
association with UBLs breaks the symmetry of the N-terminal
dimer, and the stoichiometry of the resulting complex (i.e.,
SGTA dimer binds to one UBL domain) was confirmed using
several techniques such as solution nuclear magnetic resonance
(NMR), isothermal titration calorimetry (ITC), and microscale
thermophoresis (MST; Simon et al., 2013a,b; Darby et al.,
2014).
TPR DOMAIN
TPR domains are versatile in both structure and function, they
are found widely in multi-subunit protein assemblies and consist
of between 3 and 16 tandem repeats, with each repeat made
of 34 amino acid residues forming a helix-turn-helix motif
(Das et al., 1998; D’Andrea and Regan, 2003). They mediate
specific protein-protein interactions, exploiting their structural
variability to define their functionality and a minimum of three
tandem repeats is required for their function (Blatch and Lässle,
1999). Normally, a solubility/stability helix is present at the C-
terminus of most TPRs, which may be an essential feature of
the domain (Das et al., 1998). The TPR consensus sequence is
variable but reveals a pattern of large and small hydrophobic
amino acid residues, which are highly conserved at key positions
vital for both structure and function. Other positions are less
conserved and substitution within a class of amino acids with
similar properties is tolerated, thus, consistency in size and
overall hydrophobicity can be observed (Sikorski et al., 1990;
Blatch and Lässle, 1999).
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TABLE 1 | A summary of structurally characterized domains of SGTA/Sgt2.
Protein/Species Domain Residues Technique PDB
SGTA Homo sapiens
N-terminal
3–54 X-ray crystallography 4GOD
1–69 Solution NMR spectroscopy 4CPG
TPR 80–210 X-ray crystallography 2VYI
Sgt2 Saccharomyces cerevisiae
N-terminal
1–78 Solution NMR spectroscopy 4ASV
2–72 Solution NMR spectroscopy 2LXB
Sgt2 Aspergillus fumigatus TPR 104–254 X-ray crystallography 3SZ7
FIGURE 2 | N-terminal homodimerization domain of SGTA. (A) Two orthogonal views representing the solution NMR structure of the N-terminal domain of
mammalian SGTA (PDB accession code 4CPG) are shown in blue indicating the four alpha helices present in each protomer (α1–α4 ). (B) Hydrophobic residues
present in the inner region of the mammalian N-terminal dimer, forming a tight core, are shown as sticks. (C) Overlay of solution NMR structures of N-terminal dimers
from mammalian SGTA (blue) and yeast Sgt2 (orange-red, PDB accession code 4ASV), are shown as two orthogonal views. An RMSD of 2.41Å is observed between
these two structures. (D) The ubiquitin binding domain (UBD) of the N-terminal dimer of mammalian SGTA (in blue) shown in complex with a cognate UBL domain (in
green), with residues exhibiting a strong electrostatic component at the binding interface shown as sticks (inset; Darby et al., 2014).
The structure of the TPR domain of human SGTA was solved
in 2008 by X-ray crystallography (Figure 3A; Dutta and Tan,
2008). It consists of three TPR motifs arranged in tandem, each
formed by a pair of α-helices folded in an antiparallel fashion,
in which the three TPR repeats are almost structurally identical.
This is followed by a C-terminal capping helix (helix 7) that
packs against the second helix of the third TPR motif. The seven
helices arrange into a right-handed superhelical structure with a
concave surface lined by helices α1, α3, α5, and α7 as in other
TPR domains (D’Andrea and Regan, 2003; Dutta and Tan, 2008).
The structure of the TPR domain of Sgt2 from a fungal homolog
A. fumigatus has also been determined by X-ray crystallography
revealing a similar architecture compared to the TPR domain
of human SGTA (38% sequence identity, 60% similarity and a
Cα RMSD value of 1.2Å). The main differences between these
two structures can be observed at their C-terminal regions, in
which the fungal homolog has a capping helix (α7) five residues
longer, and is positioned at a 10◦ angular increment relative to
the α6 helix when compared to the human TPR crystal structure
(Figure 3B; Chartron et al., 2011).
In comparison to known TPR domain structures, despite
their low sequence similarity, the fold of the human SGTA
TPR domain was found to be highly similar to two other
co-chaperone TPR domains, namely the carboxyl-terminus of
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FIGURE 3 | The TPR domain of SGTA. (A) The X-ray crystal structure of the TPR domain of human SGTA is shown as two orthogonal views (PDB accession code
2VYI). The three helix-turn-helix repeats formed by helices α1/α2,α3/α4, and α5/α6 can be observed in the structure, followed by a capping helix (α7), to form a right
handed superhelical assembly (Dutta and Tan, 2008). (B) TPR domain crystal structure of human SGTA (shown in orange) superimposed with that of A. fumigatus
Sgt2 (shown in red; PDB accession code 3SZ7). The TPR structure of the fungal homolog presents a longer capping helix oriented at a 10◦ angular increment when
compared to the equivalent region of human SGTA-TPR (Chartron et al., 2011).
Hsp70 interacting protein (CHIP) and Hsp70/90 organizing
protein HOP (Dutta and Tan, 2008). Both structures bind to
EEVD, the C-terminal binding motif of Hsp70 and Hsp90
chaperones, an interaction that occurs through highly conserved
key residues (Scheufler et al., 2000; Zhang et al., 2005).
Superposition of SGTA-TPR with CHIP-TPR bound to EEVD
revealed that essential binding residues are also present in SGTA-
TPR, suggesting that human SGTA may bind to Hsp70/90 in a
similar fashion to CHIP and HOP. Subsequently, two different
studies confirmed SGTA-TPR binding to Hsp70 and Hsp90
soon after the structure was solved, and both studies suggested
binding to occur through the EEVD motif (Liu et al., 1999;
Liou and Wang, 2005). These binding interactions of SGTA
through its TPR motif appear to provide a physical link with
ATP-dependent molecular chaperones which may attest to its
co-chaperone functionality. Apart from serving as a chaperone
binding platform, the TPR domain also interacts with several
proteins such as hormone receptors, viral proteins and myostatin
(Wang et al., 2003). Interactions with viral proteins have
been based on pulldowns, Co-IP and yeast two hybrid assays,
localizing the TPR domain of SGTA as the binding platform
for Vpu and Gag from HIV (Handley et al., 2001), ORF7a
from SARS-CoV (Fielding et al., 2006), NS1 from parvovirus
H-1 (Cziepluch et al., 1998) and for the human endogenous
retrovirus protein HERV-K (HML-2; Hanke et al., 2013). While
the interaction of ORF7a from SARS-CoV has been mapped to
the second TPR motif (Fielding et al., 2006), structural details
of protein-protein interactions with other viral proteins remain
unclear. Similarly, in the case of TPR domain interactions with
hormone receptors, apart from the first TPR motif interacting
with the growth hormone receptor (Schantl et al., 2003), very
little is known about binding modes with these proteins. In many
cases, the possibility of binding indirectly through other linking
proteins cannot be ruled out and further work is necessary to
characterize the interactions.
C-TERMINAL DOMAIN
The C-terminal domain of SGTA includes a glutamine-rich
region, which consists of a stretch of 39 amino acids punctuated
by 12 glutamine residues (Cziepluch et al., 1998; Liou and
Wang, 2005). The functional significance of the C-terminal
domain was investigated by yeast two-hybrid (Y2H) screening,
sampling different sized fragments of SGTA that were expressed
and screened against a library of proteins. Full length SGTA
and fragments containing the C-terminal domain were found
to interact with polypeptide fragments containing six or more
consecutive non-polar residues. SGTA with its C-terminus
removed did not interact with the hydrophobic fragments
showing that the C-terminus was necessary for interaction with
hydrophobic substrates (Liou and Wang, 2005). This capability
of the C-terminal domain facilitates interactions of SGTA in
the BAG6 quality control cycle of MLPs, its ability to shield
TMD helices of TA proteins facilitating their post-translational
membrane integration, and its interaction with the cysteine-
string protein, a chaperone implicated in neurotransmitter
release (Tobaben et al., 2003; Wang et al., 2010). The cysteine
string protein was also identified by Y2H screening as a binding
partner for the C-terminal domain (Tobaben et al., 2001). Its
site of interaction was mapped to a string of 14 cysteine residues
embedded within a hydrophobic region; removal of this region
disrupted its interaction with SGTA (Tobaben et al., 2003). SGTA
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C-terminal domain has also been shown to interact with exposed
hydrophobic regions on myostatin (together with the third TPR
repeat), and on an integral membrane protein of the rat type 1
glucose transporter (Wang et al., 2003; Liou and Wang, 2005).
The complete lack of high-resolution structural information
on this region of SGTA means molecular details pertaining to its
interactions with hydrophobic substrates remain unclear. There
are many outstanding questions with regard to this vital, yet
poorly understood, substrate-binding domain of SGTA. These
include mechanisms of TA-protein recognition and sorting, and
the binding and release of MLPs determining their ultimate fate.
SGTA IN PROTEIN HOMEOSTASIS AND
QUALITY CONTROL
SGTA interacts with a range of chaperone networks and pathways
through its central TPR domain (Figure 4; Liou and Wang,
2005). However, as mentioned earlier, SGTA’s role in the quality
control of hydrophobic substrates is first mediated by its C-
terminal domain. The ability of SGTA to recognize and shield
surface exposed regions of hydrophobicity, termed “degrons,”
on MLPs prevents substrate aggregation and promotes normal
cellular proteostasis (Chartron et al., 2011; Kawahara et al., 2013;
Wunderley et al., 2014). This aspect of SGTA function is carried
out in concert with the BAG6 complex.
The heterotrimeric BAG6 complex is composed of BAG6
(BCL2-associated athanogene), TRC35 (transmembrane
recognition complex 35) and UBL4A (ubiquitin-like protein
4A) proteins, and plays an integral role in maintaining cellular
protein homeostasis through its involvement in different quality
control pathways (Mariappan et al., 2010; Payapilly and High,
2014). As SGTA can bind to both UBLs in the BAG6 complex
(BAG6_UBL and UBL4A_UBL) through its homodimerization
domain, this provides a direct link between the two quality
control factors. In this SGTA/BAG6 cycle, SGTA directs MLPs
toward deubiquitination and hence stabilization while BAG6
directs MLPs toward polyubiquitination and proteasomal
degradation. BAG6 recognizes MLPs and recruits an E3
ubiquitin ligase, RNF126, which facilitates substrate access to
the ubiquitin-proteasome system (UPS; Rodrigo-Brenni et al.,
2014). SGTA is capable of reversing ubiquitination initiated by
the BAG6 complex, thus rescuing proteins from degradation
via an as yet unidentified deubiquitinating enzyme (DUB;
Leznicki and High, 2012). Therefore, it has been suggested that
SGTA/BAG6 dependent cycles of substrate ubiquitination and
deubiquitination may be responsible for the kinetic partitioning
of correctly folded precursors and terminally misfolded
substrates (Wunderley et al., 2014; Leznicki et al., 2015). Thus,
SGTA is intricately associated with the quality control function
of BAG6 in deciding the fate of hydrophobic substrates, either
promoting them toward maturation leading to correct insertion
into the ER, or marking them for degradation (Hessa et al., 2011;
Leznicki and High, 2012; Leznicki et al., 2013; Wunderley et al.,
2014).
SGTA and the BAG6 complex also assist the endoplasmic
reticulum-associated degradation pathway (ERAD), in
which terminally misfolded proteins are ubiquitinated and
retrotranslocated out of the ER into the cytosol leading to their
proteasomal degradation (Xu et al., 2012; Payapilly and High,
2014). Once retrotranslocated into the cytosol, ERAD substrates
are known to associate with BAG6, which maintains them in a
soluble state preventing their aggregation (Payapilly and High,
2014). Recent studies indicate a role of SGTA in modulating the
fate of ERAD substrates, in which SGTA overexpression has been
shown to delay their proteosomal degradation (Wunderley et al.,
2014).
SGTA ACTS AT THE PROTEASOME
Recent discoveries indicate that SGTA associates with the
19S regulatory particle of the 26S proteasome through a
direct interaction between its TPR domain and the C-terminal
domain of the intrinsic proteasomal ubiquitin receptor RPN13
(Leznicki et al., 2015). Furthermore, it is known that the BAG6
subunit of the heterotrimeric BAG6 complex interacts with
the intrinsic proteasomal ubiquitin receptor RPN10 (Kikukawa
et al., 2005; Minami et al., 2010). On this basis, a dynamic
quality control cycle operating at the 19S regulatory particle of
the proteasome has been proposed, capable of determining the
fate of MLPs targeted for degradation (Leznicki et al., 2015).
This model suggests that an SGTA/BAG6 cycle operating at
the proteasome may regulate access of MLPs to the proteolytic
core, allowing substrates several rescue attempts before being
committed to proteasomal degradation. This potential rescue
pathway is in turn aided by the proteasome associated
deubiquitinase UCH37/UCHL5, that also collaborates with
RPN13 (Bhattacharyya et al., 2014), providing a mechanism for
multiple cycles of ubiquitination and deubiquitination through
the concerted actions of SGTA and the heterotrimeric BAG6
complex. This proposed pathway could potentially facilitate the
rescue of viable substrates from proteasomal degradation.
SGTA IN THE BIOGENESIS OF
TAIL-ANCHORED MEMBRANE PROTEINS
SGTA plays an important role in the post-translational
integration of tail-anchored membrane (TA) proteins
(Wang et al., 2010; Johnson et al., 2013). TA proteins are a
family of membrane proteins characterized by a functional
cytoplasmic domain tethered to the lipid bilayer by a single
pass transmembrane domain (TMD) helix of moderate
hydrophobicity present at their extreme C-terminus, a region
which also includes the membrane targeting signal (Hegde
and Keenan, 2011). TA proteins constitute around 5% of all
human membrane proteins, including SNAREs, ER translocon
components and signaling proteins (Simpson et al., 2010). In
mammals, these proteins are delivered to the ER membrane by a
conserved transmembrane domain recognition complex (TRC)
pathway in which SGTA, together with the BAG6 complex,
plays a vital role in shielding TMD regions on newly synthesized
TA proteins from the aqueous cytosol as they are released
by the ribosome. This facilitates TA protein transfer to the
Frontiers in Molecular Biosciences | www.frontiersin.org 6 December 2015 | Volume 2 | Article 71
Roberts et al. SGTA Review
FIGURE 4 | Schematic representation of SGTA’s biological roles. SGTA is involved in the quality control of hydrophobic substrates (MLPs, ERAD substrates), a
process mediated by its C-terminal domain in collaboration with the BAG6 complex (Payapilly and High, 2014; Wunderley et al., 2014). The heterotrimeric BAG6
complex is composed of BAG6, TRC35, and UBL4A proteins, and interacts with SGTA via its UBLs (Darby et al., 2014). Hydrophobic substrates bound to the BAG6
complex are ubiquitinated by the actions of the E3 ligase RNF126, thus targeted for proteasomal degradation (Rodrigo-Brenni et al., 2014). SGTA interacts with the
RPN13 subunit of the 19S regulatory particle of the proteasome through its TPR domain, which has led to the proposal of an SGTA/BAG6 cycle operating at the
proteasome (Leznicki et al., 2015). Additionally, SGTA’s role extends to the shielding of exposed hydrophobic regions on TA proteins facilitating their post-translational
integration into the ER (Hegde and Keenan, 2011). This enables the handover of TA proteins to the downstream TRC40 targeting complex (Stefanovic and Hegde,
2007). Furthermore, SGTA has been implicated in hormone receptor signaling (Schantl et al., 2003; Buchanan et al., 2007; Paul et al., 2014), and has been
associated with viral lifecyles (Callahan et al., 1998; Handley et al., 2001; Walczak et al., 2014). SGTA’s interactions with Hsp70/Hsp90 chaperones (Liou and Wang,
2005) via its TPR domain may provide substrate access to additional branches of the global cellular quality control network.
dedicated TRC40 (transmembrane domain recognition complex
40) targeting complex before being passed on to membrane
receptors for insertion (Stefanovic and Hegde, 2007; Leznicki
et al., 2010, 2011; Chartron et al., 2012). In yeast, the equivalent
TA insertion pathway is referred to as the guided entry of
tail-anchored proteins (GET) pathway. The GET pathway
involves handover of TA protein substrates bound to the Sgt2
co-chaperone (the yeast equivalent of SGTA) to the Get3 ATPase,
a process mediated by the Get4/Get5 complex. This is followed
by subsequent TA-protein release at the ER membrane by
the Get1/Get2 receptor complex (Simpson et al., 2010). Thus,
SGTA/Sgt2 facilitate the biogenesis of TA proteins by ensuring
their correct maturation. Also, as TA protein substrates are more
prone to premature ubiquitination, it has been suggested that
SGTA dependent deubiquitination of TA proteins provides a
mechanism for rescue and subsequent transfer to downstream
targeting factors (Leznicki and High, 2012; Wunderley et al.,
2014).
SGTA IN THE REGULATION OF HORMONE
RECEPTOR SIGNALING
SGTA interacts with steroid receptor complexes and signaling
pathways including those of the androgen receptor (AR), a
nuclear transcription factor (Paul et al., 2014). AR signaling
pathways are critical in the pathogenesis of hormone related
diseases including prostate cancer (Buchanan et al., 2007),
breast cancer and polycystic ovary syndrome, pathologies in
which SGTA has been found to be upregulated (Goodarzi
et al., 2008; Zhu et al., 2014). With respect to AR signaling,
it has been shown that SGTA interacts with the AR hinge
region through its TPR domain (Buchanan et al., 2007).
Moreover, a member of endogenous retroviruses of the HERV-
K (HML-2) family, namely the protein Rec, has been proposed
to modulate AR activity through its interaction with SGTA
(Hanke et al., 2013). Further investigations into these potential
roles of SGTA will be required to delineate its contribution
to the AR signaling pathway. In addition, SGTA has been
associated with interactions that involve endocytosis of the
growth hormone receptor. In order to understand the role
of SGTA in hormone receptor recognition, yeast two hybrid
and pull-down assays have been performed that localize
the interaction of these receptors to the TPR domain, in
particular to the first TPR motif in the case of growth
hormone receptor (Schantl et al., 2003). It has also been
shown that SGTA regulates the activity of glucocorticoid and
progesterone receptors (Paul et al., 2014). However, in the
absence of molecular details pertaining to direct physical
interactions of SGTA with hormone receptors, mechanistic
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details elucidating relevant pathophysiological states remain
poorly understood.
THE ROLE OF SGTA IN VIRAL INFECTIONS
SGTA’s association with viral infections was first described in the
context of SGTA as a binding partner for NS1, a nonstructural
protein of parvovirus H-1 essential for viral DNA replication
and transcriptional gene expression. This was based on data
suggesting SGTA localization in both the cytoplasm and nucleus
of rat fibroblasts, potentially implicating SGTA in parvoviral
replication and/or gene expression (Cziepluch et al., 1998).
Another study identified the association between SGTA and an
accessory severe acute respiratory syndrome coronavirus protein
7a (SARS-CoV 7a), with the TPR domain of SGTA being essential
for this interaction (Fielding et al., 2006). However, details
pertaining to mechanisms of binding, and ways in which SGTA
is implicated in the life cycle of these viruses still need to be
elucidated.
The function of SGTA in human immunodeficiency virus
type 1 (HIV-1) particle release has been studied in some detail
(Callahan et al., 1998; Handley et al., 2001). It is known that
SGTA is engaged in Vpu mediated enhancement of viral particle
release by an interaction with the HIV-1 Gag protein, a viral
core protein precursor. SGTA can bind to both Vpu and Gag,
and its overexpression in mammalian cell lines transfected with
HIV-1 proviral constructs has shown to reduce the efficiency
of virus particle release (Callahan et al., 1998). Additionally,
it has been proposed that SGTA can support the shuﬄing
of the viral protein Gag to the plasma membrane where it
can assembly into HIV-1 virus capsids (Handley et al., 2001).
However, in vivo association of SGTA and Gag is abolished
when Vpu is expressed in the cell. It is also known that
Vpu can affect cellular localization of SGTA and Gag proteins
(Callahan et al., 1998; Handley et al., 2001). Furthermore, the
TPR domain proved to be sufficient for SGTA’s interaction with
Vpu and Gag albeit with lower efficiency than full length SGTA,
therefore potential contributions of N- and C-terminal domains
cannot be excluded (Dutta and Tan, 2008). Interestingly, it has
also been proposed that SGTA may be involved in promoting
viral infections where it can facilitate virus transport from ER
to cytosol by assisting in membrane penetration, as recently
demonstrated in the case of Simian virus 40 (SV40;Walczak et al.,
2014).
CONCLUSIONS AND FUTURE GOALS
It is becoming increasingly apparent that SGTA is emerging as a
key effector in the cellular quality control of MLPs and also as a
protein with wider roles. These include the regulation of protein
biogenesis and maturation, modulation of protein degradation,
regulation of hormone receptor signaling and viral lifecycles
(Figure 4). However, mechanistic details pertaining to most of
these roles have yet to be fully understood.
Recent studies combining various biochemical, biophysical
and cell biological approaches have revealed much about the
role of SGTA in cellular functions as part of the SGTA/BAG6
quality control cycle. However, it is still unclear how this
cycle differentiates between different classes of hydrophobic
substrates in order to direct them along appropriate downstream
pathways. A key milestone in understanding SGTA function
will be achieved through a complete molecular understanding
of the structural and functional contributions of its C-terminal
domain, in particular, a description of how it binds hydrophobic
substrates. This will yield insight into SGTA’s substrate specificity
and how it triages different kinds of hydrophobic substrates, such
as TA proteins, MLPs, and ERAD substrates.
It is known that SGTA promotes the deubiquitination of
client proteins and hence appears to facilitate their rescue, or
at least enables further attempts at promoting the acquisition
of a functional fold. This relies on deubiquitinating enzymes
(DUBs) that collaborate with components of the SGTA/BAG6
cycle. Further investigation is necessary to identify these DUBs
and understand their contribution to this process.
SGTA has long been associated with Hsp70 and Hsp90
chaperones (Liu et al., 1999; Liou andWang, 2005). It is tempting
to speculate that collaboration with these chaperones will enable
SGTA substrates access to additional quality control pathways.
Thus, elucidation of the precise mechanism whereby SGTA
substrates interact with Hsp70/Hsp90 chaperones will improve
our understanding of proteostasis networks in which these
components operate. Similarly, a detail description of SGTA’s
role in hormone receptor signaling is essential to understand its
regulatory function in hormonally induced disease states. With
more details relating to SGTA’s role in viral lifecycles emerging
(Walczak et al., 2014), extensive biochemical characterization is
necessary to arrive at the complete picture.
Solving the structure of full-length SGTA by a variety of
methods will go a long way toward understanding its interactions
with all the binding partners in macromolecular detail and
shed light on the overall mechanical capabilities of the dimer.
The piecemeal structures that currently exist for SGTA and
BAG6 complex components have been useful first steps in
understanding their roles but larger complex structures will add
a great deal and represent an urgent goal for researchers in this
area. Overall, it is imperative to get an improved understanding
of the proteostatic networks in which SGTA operates under
physiological conditions, to further our understanding of how
these pathways are reconfigured in various disease states. It is
hoped that these insights into pathologies will ultimately feed in
to the design of therapeutics.
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